Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Pbm topic
No spam. Unsubscribe anytime.
Committee advances PBM transparency and PEIA oversight bill after mixed testimony
Summary
House Bill 5430, revising PBM contracting, rebate handling and PEIA oversight, was amended and reported out of committee after testimony from independent pharmacists who urged transparency and from PBM trade groups warning of unintended cost effects; the Insurance Commission reviewed past market-conduct work.
House Bill 5430, which would change how the Public Employees Insurance Agency (PEIA) and West Virginia Medicaid can contract with pharmacy benefit managers (PBMs) and how rebates and group purchasing organizations are handled, was advanced by the committee after stakeholder testimony and an adopted strike‑and‑insert.
Counsel summarized the strike‑and‑insert: it would require competitive bidding for a vendor separate from the PBM, make PEIA’s PBM contracts subject to state PBM law and Insurance Commission oversight, prohibit certain spread pricing practices, and require rebate transparency and pass-through to reduce premium costs. The change also includes a one‑year pilot for certain Medicaid provisions and clarifies that 100% of some rebates be used to reduce premiums.
Independent pharmacy witnesses portrayed a sharp picture of local impact. Matt Walker of the West Virginia Independent Pharmacy Association said independent pharmacies have closed in large numbers and described practices including alleged under‑reimbursement, audits and steering patients to mail order. "Independent pharmacies are given sort of a take it or leave it deal," Walker said, urging transparency and oversight. Pharmacist and owner Devonna Miller West described operating a rural pharmacy for decades and gave concrete examples—she said her store saw $16,000 in manufacturer rebates for 12 branded drugs in five weeks after a transparency change, and argued those funds are often retained by intermediaries instead of local pharmacies or plans.
Sean Stephenson, senior director for state affairs at the Pharmaceutical Care Management Association, testified for PBMs that they aggregate purchasing power and negotiate rebates and that PBMs are compensated by spread pricing, rebate retention, or administrative fees; he cautioned that restricting compensation mechanisms can have cost consequences. Jessica Brinske of the Cardinal Institute presented research on prior state changes and warned of adverse effects and higher PEIA spending in at least one prior example.
Joylynn Fakes of the West Virginia Offices of the Insurance Commissioner said the office is already enforcing NAIDAC-plus pricing and 100% rebate pass‑through in the commercial market and that three years of data showed an actuarial wash when spread pricing was removed and rebate pass-through applied; she also noted ongoing market-conduct exams.
After stakeholder testimony and discussion, the committee adopted the strike‑and‑insert and voted to report HB 5430 to the full Senate with recommendation that it do pass as amended.
Next steps: The bill was sent to the full Senate; the committee record lists PEIA and the Office of the Insurance Commissioner as affected agencies and a minimal OIC fiscal impact.
